Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Validea
$12.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Roche Holding AG and Ferring Pharmaceuticals collaborate to develop personalised infertility treatment


Tuesday, 24 Jun 2014 04:00am EDT 

Roche Holding AG and Ferring Pharmaceuticals:Announced a collaboration to combine diagnostic testing technology from Roche with Ferring's human cell line derived recombinant follicle-stimulating hormone (human rFSH), a gonadotrophin currently in phase III development.Roche will work with Ferring and its global phase III programme to qualify, validate, document and seek regulatory approval for a companion diagnostic test to be used in combination with Ferring's human rFSH. 

Company Quote

289.9
1.6 +0.55%
21 Nov 2014